Shiyi Sun1, Jing Ma2, Xingwu Ran1. 1. Diabetic Foot Care Center, Department of Endocrinology and Metabolism, West China Hospital, Sichuan University, Chengdu Sichuan, 610041, P.R.China. 2. Department of Endocrinology and Metabolism, Gansu Provincial Hospital, Lanzhou Gansu, 730000, P.R.China.
Abstract
OBJECTIVE: To review the research progress of adrenergic β-antagonists on wounds and diabetic chronic cutaneous ulcers healing in recent years, and to investigate its application prospect in diabetic foot ulcer (DFU). METHODS: The latest literature about the role of adrenergic β-antagonists in wounds and diabetic chronic cutaneous ulcers healing was extensively reviewed, and the mechanisms of adrenergic β-antagonists for wounds and its potential benefit for DFU were analyzed thoroughly. RESULTS: The adrenergic β-antagonists can accelerate the wound healing. The possible mechanisms include accelerating re-epithelialization, promoting angiogenesis, improving neuropathy, and regulating inflammation and growth factors, etc. At present clinical research data showed that the adrenergic β-antagonists may be an adjuvant treatment for diabetic chronic cutaneous ulcers. CONCLUSION: Adrenergic β-antagonists maybe promote the healing of wounds and diabetic chronic cutaneous ulcers. However, more long-term follow-up and high-quality randomized control studies are needed to further verify their efficacy and safety for DFU.
OBJECTIVE: To review the research progress of adrenergic β-antagonists on wounds and diabetic chronic cutaneous ulcers healing in recent years, and to investigate its application prospect in diabetic foot ulcer (DFU). METHODS: The latest literature about the role of adrenergic β-antagonists in wounds and diabetic chronic cutaneous ulcers healing was extensively reviewed, and the mechanisms of adrenergic β-antagonists for wounds and its potential benefit for DFU were analyzed thoroughly. RESULTS: The adrenergic β-antagonists can accelerate the wound healing. The possible mechanisms include accelerating re-epithelialization, promoting angiogenesis, improving neuropathy, and regulating inflammation and growth factors, etc. At present clinical research data showed that the adrenergic β-antagonists may be an adjuvant treatment for diabetic chronic cutaneous ulcers. CONCLUSION: Adrenergic β-antagonists maybe promote the healing of wounds and diabetic chronic cutaneous ulcers. However, more long-term follow-up and high-quality randomized control studies are needed to further verify their efficacy and safety for DFU.
Authors: Kara L Spiller; Rachel R Anfang; Krista J Spiller; Johnathan Ng; Kenneth R Nakazawa; Jeffrey W Daulton; Gordana Vunjak-Novakovic Journal: Biomaterials Date: 2014-02-28 Impact factor: 12.479
Authors: Angela Djanani; Nicole C Kaneider; Christian Meierhofer; Daniel Sturn; Stefan Dunzendorfer; Helmut Allmeier; Christian J Wiedermann Journal: Pharmacology Date: 2003-08 Impact factor: 2.547